Home Cart Sign in  
Chemical Structure| 35905-85-2 Chemical Structure| 35905-85-2

Structure of 35905-85-2

Chemical Structure| 35905-85-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 35905-85-2 ]

CAS No. :35905-85-2
Formula : C6H4BrNO2
M.W : 202.01
SMILES Code : OC(=O)C1=CC=CN=C1Br
MDL No. :MFCD01646068
InChI Key :MMWNKXIFVYQOTK-UHFFFAOYSA-N
Pubchem ID :233262

Safety of [ 35905-85-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 35905-85-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 38.9
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

50.19 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.15
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.4
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.54
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.34
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.43
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.03

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.35
Solubility 0.897 mg/ml ; 0.00444 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.06
Solubility 1.77 mg/ml ; 0.00875 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.26
Solubility 1.12 mg/ml ; 0.00555 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.54 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.49

Application In Synthesis of [ 35905-85-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 35905-85-2 ]
  • Downstream synthetic route of [ 35905-85-2 ]

[ 35905-85-2 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 35905-85-2 ]
  • [ 75-65-0 ]
  • [ 116026-98-3 ]
YieldReaction ConditionsOperation in experiment
99% at 80℃; for 3 h; Intermediate 28:; (2-Bromo-pyridin-3-vl)-carbamic acid tert-butyl ester:; To the known starting material 2-bromo-nicotinic acid (J. Org. Chem.; 14; 1949; 509, 513) (3.0 g, 13.0 mmol) in 26 ml of t-BuOH was added diphenylphosporyl azide (3.9 g, 14.3 mmol). The resulting solution was heated in an oil bath at 80°C for 3 h. Upon cooling, the reaction solution was then concentrated and rediluted in EtOAc and washed with H2O (50 ml_), followed by saturated aqueous NaHCO3 (30 ml) and brine (30 ml_). Combined organics were then dried over Na2SO4, filtered and concentrated under reduced pressure. Purification was accomplished by flash chromatography on a 35L Biotage silica gel column eluting with 20percent EtOAc/Hexanes and collecting 18 mL fractions. Product containing fractions (19-29) were combined and concentrated under reduced pressure to give colorless oil (3.5 g, 12.8 mmol, 99percent yield); Rf 0.75 (20percent EtOAc/Hexanes); LRMS m/z (APCI*) 274/275 [M+ H]; 400 MHz 1HNMR (CDCI3) 6 8.44 (dd, J= 7.9, 1.5 Hz, 1H); 8.02 (dd, J=4.6, 1.7 Hz, 1H); 7.23 (dd, J=8.3, 4.6 Hz, 1 H); 7.03 (bs, 1 H); 1.53 (s, 9H).
76% for 2 h; Heating / reflux 2-bromo-3-methylpyridine (25.0 mL, 213 mmol) was added to a solution of potassium permanganate (87.7 g, 555 mmol) in 800 ML of water and the mixture was stirred under reflux. After 5 hours, 600 mL of water was distilled off and the remaining suspension was filtered. The residue was washed with two 50 mL portions of hot water and the combined filtrates were acidified with concentrated HC1. The white precipitate was filtered and dried in a vacuum oven to give 26.8 g of 2-bromonicotinic acid (62percent yield). DIPHENYLPHOSPHORYLAZIDE was added to a solution of 2-bromonicotinic acid (15.0 g, 74.0 mmol) and triethylamine (11.4 mL, 81. 4 mmol) in 140 mL of anhydrous tert-butanol. The reaction mixture was stirred under reflux for 2 hours, cooled to room temperature, and concentrated in VACUO. The residue was dissolved in 150 ML of ethyl acetate and washed with three 50 mL portions of water, three 50 mL portions of saturated aqueous sodium bicarbonate, and with two 50 mL portions of brine. The organic layer was dried over magnesium sulfate (MGS04), filtered, and concentrated in vacuo. The residue crystallized upon standing to give 15.3 g of the title product (76percent yield).
References: [1] Patent: WO2004/110996, 2004, A1, . Location in patent: Page/Page column 28.
[2] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2136 - 2145.
[3] Patent: WO2005/30213, 2005, A1, . Location in patent: Page/Page column 165.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 35905-85-2 ]

Bromides

Chemical Structure| 52718-95-3

A619777 [52718-95-3]

Methyl 2-bromonicotinate

Similarity: 0.92

Chemical Structure| 53087-78-8

A242380 [53087-78-8]

Ethyl 2-bromonicotinate

Similarity: 0.89

Chemical Structure| 55304-85-3

A189218 [55304-85-3]

2,6-Dibromo-3-pyridinecarboxylic acid

Similarity: 0.85

Chemical Structure| 128071-75-0

A207032 [128071-75-0]

2-Bromonicotinaldehyde

Similarity: 0.81

Chemical Structure| 942473-59-8

A135506 [942473-59-8]

2,5-Dibromoisonicotinic acid

Similarity: 0.77

Carboxylic Acids

Chemical Structure| 55304-85-3

A189218 [55304-85-3]

2,6-Dibromo-3-pyridinecarboxylic acid

Similarity: 0.85

Chemical Structure| 942473-59-8

A135506 [942473-59-8]

2,5-Dibromoisonicotinic acid

Similarity: 0.77

Chemical Structure| 3222-50-2

A158923 [3222-50-2]

4-Methylnicotinic acid

Similarity: 0.74

Chemical Structure| 3222-49-9

A358069 [3222-49-9]

5-Methylnicotinic acid

Similarity: 0.73

Chemical Structure| 24242-19-1

A167000 [24242-19-1]

5-Amino-3-pyridinecarboxylic acid

Similarity: 0.72

Related Parent Nucleus of
[ 35905-85-2 ]

Pyridines

Chemical Structure| 52718-95-3

A619777 [52718-95-3]

Methyl 2-bromonicotinate

Similarity: 0.92

Chemical Structure| 53087-78-8

A242380 [53087-78-8]

Ethyl 2-bromonicotinate

Similarity: 0.89

Chemical Structure| 55304-85-3

A189218 [55304-85-3]

2,6-Dibromo-3-pyridinecarboxylic acid

Similarity: 0.85

Chemical Structure| 128071-75-0

A207032 [128071-75-0]

2-Bromonicotinaldehyde

Similarity: 0.81

Chemical Structure| 942473-59-8

A135506 [942473-59-8]

2,5-Dibromoisonicotinic acid

Similarity: 0.77